ETHZW (ETHZW)

Overview

180 Life Sciences Corp. is a forward-thinking biotechnology company that stands on the frontier of developing innovative therapeutics aimed at addressing chronic pain, inflammation, fibrosis, and other inflammatory diseases, which represent significant unmet medical needs. Operating from its headquarters in Palo Alto, California, the company is actively engaged in carrying out clinical and preclinical trials to push the boundaries of medical research and offer novel solutions aimed at improving patient outcomes in areas where conventional treatments fall short.

Products and Services

• Fibrosis and Anti-Tumor Necrosis Factor (Anti-TNF) Platform

  This platform is the cornerstone of 180 Life Sciences' effort in combating fibrosis and inflammatory diseases through the inhibition of tumor necrosis factor (TNF). It has successfully completed Phase IIb clinical trials, underscoring its potential in providing effective therapies for conditions underscored by fibrosis and chronic inflammation.

• Synthetic Cannabidiol (CBD) Analogs Platform

  With a focus on leveraging the therapeutic potential of cannabinoids, this platform involves the development of synthetic pharmaceutical-grade molecules that are close or distant analogs of non-psychoactive cannabinoids, such as CBD. These analogs are being developed for the treatment of inflammatory diseases and pain, tapping into the anti-inflammatory and analgesic properties of cannabinoids without the psychoactive effects associated with THC.

• a7nAChR Platform

  Targeting the alpha 7 nicotinic acetylcholine receptor (a7nAChR), this immune suppressive platform is in the preclinical trial phase. It focuses on exploiting the receptor's role in regulating immune responses, with the potential to offer new therapeutic approaches for diseases characterized by excessive or aberrant inflammation.